Intermittent claudication in older patients - Practical treatment guidelines

被引:10
作者
Boccalon, H [1 ]
机构
[1] Univ Hosp Rangueil, Dept Angiol, F-31403 Toulouse 4, France
关键词
D O I
10.2165/00002512-199914040-00002
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The prevalence of intermittent claudication (IC) increases with age; when questioned, older patients consider increased difficulty in walking to be a normal consequence of aging. Although the prognosis for the involved limb with IC is relatively good, IC is an important clinical predictor of increased cardiovascular mortality. It is important to effect a minimal strategy for determining the presence of lesions in different vascular regions: carotids, coronaries, aorta and renal arteries. The goals for the treatment of IC in the elderly are to improve the walking distance and quality of life and to increase survival. Practical guidelines for the treatment of IC are to first establish a correct diagnosis. Then, patients have to apply life-style modifications and participate in an exercise programme, with the next treatment step involving the use of antiplatelet drugs. However, it must be remembered that older patients could have limitations on exercise; in such cases, a vasoactive drug should be considered. The third guideline consists of multifocal evaluation of the arteries, specifically the coronaries, carotids and abdominal aorta. The existence of an iliac obstruction or stenosis requires consideration of the 2 last guidelines. In more than 75% of cases, elderly patients have femoropopriteal or distal arterial obstructions: exercise and a vasoactive drug should be employed in these instances. The presence of iliac lesions has to be discussed in the presence of a multidisciplinary team in a vascular centre, and should consider the usefulness of percutaneous transluminal angioplasty or surgery.
引用
收藏
页码:247 / 259
页数:13
相关论文
共 54 条
[1]   COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].
ALTMAN, R ;
CARRERAS, L ;
DIAZ, R ;
FIGUEROA, E ;
PAOLASSO, E ;
PARODI, JC ;
CADE, JF ;
DONNAN, G ;
EADIE, MJ ;
GAVAGHAN, TP ;
OSULLIVAN, EF ;
PARKIN, D ;
RENNY, JTG ;
SILAGY, C ;
VINAZZER, H ;
ZEKERT, F ;
ADRIAENSEN, H ;
BERTRANDHARDY, JM ;
BRAN, M ;
DAVID, JL ;
DRICOT, J ;
LAVENNEPARDONGE, E ;
LIMET, R ;
LOWENTHAL, A ;
MORIAU, M ;
SCHAPIRA, S ;
SMETS, P ;
SYMOENS, J ;
VERHAEGHE, R ;
VERSTRAETE, M ;
ATALLAH, A ;
BARNETT, H ;
BATISTA, R ;
BLAKELY, J ;
CAIRNS, JA ;
COTE, R ;
CROUCH, J ;
EVANS, G ;
FINDLAY, JM ;
GENT, M ;
LANGLOIS, Y ;
LECLERC, J ;
NORRIS, J ;
PINEO, GF ;
POWERS, PJ ;
ROBERTS, R ;
SCHWARTZ, L ;
SICURELLA, J ;
TAYLOR, W ;
THEROUX, P .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100
[2]   THE IMPACT OF INTERMITTENT CLAUDICATION ON QUALITY-OF-LIFE EVALUATED BY THE SICKNESS-IMPACT-PROFILE TECHNIQUE [J].
ARFVIDSSON, B ;
KARLSSON, J ;
DAHLLOF, AG ;
LUNDHOLM, K ;
SULLIVAN, M .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1993, 23 (11) :741-745
[3]   Oral naftidrofuryl - A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease [J].
Barradell, LB ;
Brogden, RN .
DRUGS & AGING, 1996, 8 (04) :299-322
[4]   REDUCTION OF REQUIREMENT FOR LEG VASCULAR-SURGERY DURING LONG-TERM TREATMENT OF CLAUDICANT PATIENTS WITH TICLOPIDINE - RESULTS FROM THE SWEDISH TICLOPIDINE MULTICENTER STUDY (STIMS) [J].
BERGQVIST, D ;
ALMGREN, B ;
DICKINSON, JP .
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 1995, 10 (01) :69-76
[5]   PHARMACOLOGICAL APPROACHES TO THE TREATMENT OF INTERMITTENT CLAUDICATION [J].
BEVAN, EG ;
WALLER, PC ;
RAMSAY, LE .
DRUGS & AGING, 1992, 2 (02) :125-136
[6]  
Blume J, 1996, VASA-J VASCULAR DIS, V25, P265
[7]  
BOCCALON H, 1997, DIS MANAG HEALTH OUT, V2, P47
[8]   Intermittent claudication in 8343 men and 21 year specific mortality follow-up [J].
Bowlin, SJ ;
Medalie, JH ;
Flocke, SA ;
Zyzanski, SJ ;
Yaari, S ;
Goldbourt, U .
ANNALS OF EPIDEMIOLOGY, 1997, 7 (03) :180-187
[9]   Carnitine-related alterations in patients with intermittent claudication [J].
Brevetti, G ;
diLisa, F ;
Perna, S ;
Menabo, R ;
Barbato, R ;
Martone, VD ;
Siliprandi, N .
CIRCULATION, 1996, 93 (09) :1685-1689
[10]   DRUG-TREATMENT OF INTERMITTENT CLAUDICATION - A CRITICAL ANALYSIS OF THE METHODS AND FINDINGS OF PUBLISHED CLINICAL-TRIALS, 1965-1985 [J].
CAMERON, HA ;
WALLER, PC ;
RAMSAY, LE .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 26 (05) :569-576